Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

DAPARHT: DAPAgliflozin for Renal Protection in Heart Transplant Recipients

NCT05321706 is registered in ClinicalTrials.gov with Oslo University Hospital as lead sponsor.

NCT NCT05321706
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05321706 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
DAPARHT: DAPAgliflozin for Renal Protection in Heart Transplant Recipients
Lead sponsor
Oslo University Hospital
Phase
Phase 3
Overall status
Active, not recruiting
Start date
June 8, 2022
Completion date
November 30, 2028
Enrollment
430 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

heart transplant failure, kidney failure